Thromboembolism in inflammatory bowel diseases: a report from Saudi Arabia by Issa, Hussain et al.
© 2011 Issa et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical and Experimental Gastroenterology 2011:4 1–7
Clinical and Experimental Gastroenterology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
CAsE sErIEs
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CEG.S14918
Thromboembolism in inflammatory bowel 
diseases: a report from saudi Arabia
Hussain Issa1
sami Al-Momen1
Bahaa Bseiso1
Ghada Ali Al-Janobi1
Mohammed A Aljama1
Fadel Ali Almousa1
Mahdi E Al-Jarodi1
Ahmed H Al-salem2
1Department of Internal Medicine, 
King Fahad specialist Hospital, 
Dammam, saudi Arabia; 2Department 
of Pediatric surgery, Maternity and 
Children Hospital, Dammam, saudi 
Arabia
Correspondence: Ahmed H Al-salem 
PO Box 61015, Qatif 31911,  
saudi Arabia 
Mobile +00966505818009 
Email ahsalsalem@hotmail.com
Abstract: Thromboembolism (TE) is a serious but under-recognized complication of 
  inflammatory bowel disease (IBD). This is specially so in developing countries where the 
incidence of IBD is low. In Saudi Arabia, IBD is considered to be rare, but the incidence is 
increasing. Where the clinical manifestations resemble those of developed countries, TE as a 
complication of IBD is considered to be very rare. This report describes six IBD patients with 
TE. This importance of the complication of TE is stressed, and physicians caring for these 
patients should be aware of it in order to obviate potential morbidity and mortality.
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Introduction
Thromboembolism (TE) is now a well-recognized complication of inflammatory 
bowel disease (IBD) to the extent that it is considered an extraintestinal manifestation 
of IBD.1,2 The reported frequency of TE in IBD varies widely in the literature, but 
patients with ulcerative colitis (UC) and Crohn’s disease (CD) have a three-fold risk 
of developing TE when compared with the general population.3,4 TE represents a 
significant cause of morbidity and mortality, and among IBD patients mortality 
  following an acute TE ranges from 8% to 25%.1,5 One factor contributing to this is 
the fact that the diagnosis of TE in these patients is either overlooked or delayed, as 
these patients are usually unwell and on several medications, and new symptoms are 
  usually attributed to their disease or to the side effects of their medications. TE in 
IBD appears to be disease specific, and although there seems to be an equal risk of 
developing TE in UC and CD, there are reports suggesting that UC patients are at a 
greater risk for TE when compared with CD patients.4,6 In Saudi Arabia, IBD is 
considered to be rare, but there is a definite and appreciable increase in the incidence 
of IBD.7–9 The manifestations of IBD in Saudis are reported to be similar to those of 
developed countries, but in none of the published series so far was there a report of 
TE as a complication of IBD.7–9 There were two case reports, however: an aortic 
thrombosis complicating CD disease10 and a cerebral venous thrombosis as a com-
plication of UC.11 This report describes our experience with TE in six patients with 
IBD complicated by pulmonary embolism in four of them. The prevalence of TE 
complications in IBD in Saudi Arabia is not known, and this report should stimulate 
further national studies to determine this.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Case reports
Case no. 1
A 23-year-old, nonsmoking, Saudi male was referred to 
our hospital complaining of abdominal pain for 18 months. 
He was well until 14 months prior to presentation, when he 
started to complain of intermittent colicky, mostly right-
sided abdominal pain, not related to meals and associated 
with occasional nausea, vomiting, and frequent bowel 
motion up to six or seven times daily but without blood or 
mucous. Four months after developing the pain, his appetite 
decreased and he lost 30 kg in weight. His family history 
was unremarkable except for a history of CD in third-degree 
relatives. On examination he was found to be thin built and 
not in distress, and his vital signs were normal. His abdo-
men was mildly tender in the right upper quadrant with no 
palpable masses or organomegaly. Laboratory investiga-
tions showed the following: white blood cell count (WBC) 
5.34 × 109/L, hemoglobin (Hb) 7.4 g/dL, hematocrit 24.7%, 
platelets 701 × 109/L, erythrocyte sedimentation rate (ESR) 
75 mm/h, total bilirubin 1.5 umol/L, alkaline phosphatase 
100 unit/L, alanine aminotransferase 25 unit/L, aspartate 
aminotransferase 24 unit/L, γ-glutamyl transpeptidase 16 
unit/L, total protein 56 g/L, albumin 15 g/L, phosphorus 
1.29 mmol/L, calcium 1.93 mmol/L, antithrombin III 
90.1 sec (normal 75–125), activated protein C resistance 
88 (normal 70–140), and protein S 54.8 L (normal 50–120). 
Lower gastrointestinal endoscopy showed ileitis with nodu-
lar terminal ileal mucosa and aphthous ulcers with normal 
colon. Multiple biopsies were taken and the histopathology 
revealed CD. Computed tomography (CT) enterography 
showed segmental wall thickening of the ileal loops with 
creeping fat and enlarged mesenteric lymph nodes most 
likely representing CD as well as partial obstruction at the 
distal ileum with significant dilated proximal bowel loops. 
There was also inferior vena cava thrombosis with central 
intraluminal filling defect extending to the right internal 
iliac vein (Figures 1 and 2). Pulmonary CT revealed small 
subsegmental pulmonary emboli. This was treated with 
low-molecular-weight heparin. There was no family history 
of TE. He was started on Pentasa, gradually increasing the 
dose until it reached 1 g three times daily + Caltrate, iron, 
and vitamin D supplements. Azathioprine was introduced 
with a dose of 50 mg once daily. He quickly responded to 
treatment and his laboratory follow-up showed a rise in his 
hemoglobin level reaching 10 g/dL, normalization of his 
calcium level, and elevation of his albumin level reaching 
28 g/L. His inflammatory markers, including ESR and CRP, 
gradually came down.
Case no. 2
A 39-year-old, nonsmoking, Saudi male with a known case 
of CD was diagnosed 5 years previously in a local hospital. 
He was started on azathioprine, prednisolone, and   mesalazine, 
but he was not compliant to treatment. Two years later, 
Figure 1 CT scan of the abdomen showing inferior vena cava thrombosis (single 
arrow). Note also partial obstruction at the distal ileum with significant dilated 
proximal bowel loops and bowel thickening (double arrow).
Figure 2 Abdominal CT scan showing inferior vena cava thrombosis (single arrow) 
with dilated and thickened small bowel loops (double arrow).Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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he developed enterovesical fistula and was started on antitumor 
necrosis factor (TNF) (infliximab). He received four cycles 
with partial improvement and then was lost for follow-up. 
He presented to our hospital with a 20-day history of abdominal 
pain, distention, and fever with chills. He presented a history of 
intermittent fecaluria and pneumaturia for the last few months 
with a history of decreased appetite and weight loss of about 
10 kg. During examination, his abdomen was distended with 
ascites and decreased bowel sounds. He underwent a CT scan, 
which revealed an enterocolic fistula, superior mesenteric vein 
thrombosis, and a few enlarged retroperitoneal and mesenteric 
lymph nodes (Figure 3). He was scheduled for surgery and 
underwent ileocecal resection, sigmoid colectomy, terminal 
ileostomy, and colostomy. Pathology of the resected intestines 
showed changes consistent with CD with ulcerations, fissuring, 
and fistula formation. He did not receive thromboprophylaxis 
postsurgery. He was stable until the 12th postoperative day 
when he suddenly developed shortness of breath and was 
found to be tachypneic, tachycardic, and hypotensive. Spiral 
CT of the chest showed evidence of a small left upper lobe 
subsegmental pulmonary embolism (Figure 4). There was no 
family history of TE. He was started on low-molecular-weight 
heparin, and his workup showed a low level of antithrombin III 
and factor V Leiden, suggestive of underlying   thrombophilia, 
so he was started on warfarin with a stable hospital course 
and restarted on anti-TNF (infliximab). Currently, he is being 
  followed up in the clinic, is doing well, and is waiting for 
closure of his stomas.
Case no. 3
A 49-year-old, Saudi female was diagnosed as having ulcerative 
pancolitis and was referred to our hospital for further manage-
ment. She was managed with mesalazine and   prednisolone. Her 
disease was nonremitting. She developed left cerebrovascular 
accident. A Doppler ultrasound showed total occlusion of the left 
carotid artery and a 2-D transesophageal echo showed a normal 
heart with no intramural thrombus. She was not on thrombopro-
phylaxis. During her stay at our hospital she also developed right 
popliteal deep venous thrombosis and pulmonary embolism. 
She was started on low-  molecular-weight heparin but continued 
to have hematochezia and a drop in her hemoglobin, so it was 
decided that an inferior vena cava filter should be inserted. A 
repeat colonoscopy showed moderately severe pancolitis with 
multiple pseudo polyps. Histopathology was compatible with 
UC with no dysplasia or cytomegalovirus. Her investigations 
showed the following: Hb 3.8 g/dL, mean corpuscular volume 
61.5, mean corpuscular hemoglobin 17.6, platelets 432,000/mm3, 
ESR 75, and albumin 27 g/L. Her liver function tests and renal 
profile were normal. All studies for thrombophilia were negative, 
including protein S, protein C, antithrombin III, and factor V 
Leiden. Lupus anticoagulant was negative and JAK2 mutation 
was ordered. She was started on prednisolone and azathioprine 
and was titrated up to 100 mg once daily in addition to aspirin 
100 mg once daily. She went into remission after that and steroids 
were discontinued. She was maintained on mesalazine 1 g twice 
daily and azathioprine 100 mg orally once daily.
Case no. 4
A 17-year-old female presented to our hospital with easy 
fatigability, palpitation, dizziness, and pallor, and decreased 
Figure 3 CT scan of the abdomen showing thrombosis in the superior mesenteric 
vein (arrow). Also note the ascites.
Figure 4 CT scan of the chest showing pulmonary embolism (arrow).Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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appetite for 1 month. This was associated with mild abdominal 
pain and bleeding from the rectum. She was intentionally try-
ing to lose weight and over a 3-month period she lost about 
20 kg. Clinically, she was pale but not jaundiced and was not 
in respiratory distress. Her chest and abdominal examinations 
were normal. Her investigations showed the following: WBC 
3.4 × 109/L, Hb 3.1 g/dL, platelets 106,000/mm3, calcium 
8.2 mmol/L, albumin 3.4 g/L, and total bilirubin 1.55 umol/L. 
All other investigations were normal. She received a blood 
transfusion and underwent a colonoscopy. The colonoscopy 
showed markedly congested, erythematous mucosa of the left 
colon, which was oozing fresh blood with diffuse ulceration, 
granularity, and submucosal hemorrhage. Her upper endos-
copy showed chronic gastroduodenitis. She was diagnosed as 
having UC of the left colon and was started on treatment with 
prednisolone, mesalamine, omeprazole, steroid enema, and 
mesalazine enema. She was discharged home in a good general 
condition but readmitted 2 months later with bilateral lower 
limb edema of 1-week duration. This was associated with pain 
on walking. Examination showed the following: prothrombin 
time (PT) 14.6 sec   (control = 13.4 sec) and   partial thrombo-
plastin time (PTT) 35 sec (control = 30.2 sec); antithrombin 
III was slightly reduced, but protein C, protein S, plasminogen, 
and factor V Leiden were all within normal limits. Lupus 
anticoagulation, antinuclear antibodies (ANA), and anti-DNA 
were negative. Repeated factor III was normal; ANA, antimi-
tochondrial antibodies, antiribosomal   antibodies, antibasement 
membrane antibodies, and antineutrophil (ANCA) antibodies 
were all negative. Her Hb was 9 g/dL, WBC 5.7 × 109/L, and 
platelets 223,000/mm3. She was diagnosed as having bilateral 
deep vein thrombosis. She was not using oral contraceptive 
pills, and there was no family history of TE. While in hospital 
she developed chest pain associated with shortness of breath. 
Pulmonary angiography showed evidence of pulmonary 
embolism with a filling defect and a thrombus was seen within 
the right inferior pulmonary artery. She was started on anti-
coagulant therapy and was discharged 2 weeks later with an 
international normalized ratio of 3.3. She was subsequently 
followed up in clinic and was well.
Case no. 5
A 50-year-old, Saudi female presented to the emergency 
department with a 2-month history of bloody diarrhea and 
lower abdominal pain. Clinically, she was found to be pale with 
stable vital signs and a mild generalized abdominal tenderness. 
Initial investigations showed the following: WBC 9.4 × 109/L, 
Hb 8 g/dL, ESR 79, and albumin 2.6 g/dL. Her liver and renal 
function tests were normal. Flexible   sigmoidoscopy up to the 
distal transverse colon revealed uniform involvement with 
moderately severe colitis. Histopathology was compatible 
with UC. She was started on mesalazine tablets in addition to 
prednisolone 40 mg daily. She was discharged to be followed 
up in the clinic. During prednisolone tapering she relapsed 
after 5 weeks. She presented to us again unwell with severe 
abdominal pain, vomiting, and fever. Clinically, she was found 
to have severe abdominal tenderness, guarding, and positive 
rebound tenderness. Her investigations showed the following: 
WBC 3.1 × 109/L, Hb 10.1 g/dL, PLT 152,000/mm3, INR 1.2, 
PTT 44, total bilirubin 2.13 umol/dL, direct bilirubin 2 umol/
dL, and alkaline phosphatase 41 IU/L. Abdomen X-rays 
showed air under the diaphragm. She was admitted to the 
intensive care unit (ICU), was resuscitated, and underwent an 
emergency laparotomy. There was purulent fluid in the peri-
toneal cavity and a perforation at splenic flexure. Peritoneal 
lavage and subtotal colectomy were carried out, leaving the 
cecum and 10 cm from proximal ascending colon, which was 
brought out as a colostomy. The rectal stump was left behind. 
Her postoperative course was complicated by wound infection, 
which was treated with antibiotics, and intrahepatic cholestasis 
related to total parenteral nutrition, which resolved gradu-
ally. She was maintained on mesalazine, as she had residual 
colon left behind. During her stay in the ICU she developed 
weakness in all her limbs and was difficult to be extubated. 
Neurological examination revealed high mental function with 
intact cranial nerves but weakness in all limbs 2/5 with absent 
reflexes. Electromyography and nerve conduction studies 
revealed motor polyneuropathy that was more pronounced in 
the lower limbs, compatible with critical illness polyneuropa-
thy. Her electrolytes, calcium, phosphorus, magnesium, trace 
elements, and vitamins were corrected and optimized. Physical 
therapy was intensified and, because of her prolonged stay in 
ICU, unfractionated subcutaneous heparin 5000 IU subcutane-
ously was given every 8 h. She had tracheostomy, but it was 
closed after improvement in her strength. The muscle strength 
in her limbs improved gradually, reaching 3/5 over 8 weeks 
after the operation, when she was found to have swelling and 
discoloration in her left lower limb. A Doppler ultrasound 
confirmed the presence of deep venous thrombosis in the left 
popliteal and femoral veins. Thrombophilia screening showed 
the following: protein S and C, antithrombin III, lupus anti-
coagulation, ANA, and anti-DNA were all negative. She was 
fully anticoagulated initially with heparin and subsequently 
with warfarin. Warfarin was continued for 6 months. She 
was maintained during this period on mesalazine tablets, in 
addition to suppositories. Proctoscopy and endoscopy through 
stoma revealed evidence of colitis. She underwent resection of Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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remaining colon (rectum, proximal ascending colon) and had 
ileoanal pouch anastomosis. During follow-up over 5 years, 
no recurrence of thrombosis was observed.
Case no. 6
A 17-year-old, Saudi female was diagnosed as UC 9 months 
prior to her presentation to our hospital. Colonoscopy revealed 
pancolitis. She was maintained on mesalazine 1000 mg 
three times daily but was not compliant with her medication. 
She was admitted with moderate exacerbation of UC and 
severe iron deficiency anemia. Her investigations showed 
the following: WBC 6.7 × 109/L, Hb 5.3 g/dL, ESR 60, 
and albumin 2 g/dL. Her liver and renal function tests were 
normal. She received a blood transfusion and was started on 
prednisone 40 mg once daily and iron tablets. During her 
hospital stay she developed left leg swelling and calf pain. 
A Doppler ultrasound of the left lower limb revealed complete 
obstruction of the upper half of the femoral vein and popliteal 
vein by a thrombus. Thrombophilia study, including protein S 
and C, antithrombin III, and plasminogen functional chro-
mogenic assay, was normal. Lupus anticoagulant and ANA 
were negative. She was started on unfractionated heparin to 
maintain her PTT at twice the normal limit and subsequently 
was put on warfarin 5 mg daily. She tolerated the treatment 
well but was readmitted with hematochezia 2 weeks after her 
discharge. Her INR was 1.8. As heparin was reported to have 
an anti-inflammatory effect in patients with UC, warfarin was 
held. It was decided to keep her on subcutaneous unfraction-
ated heparin at a dose of 7500 IU subcutaneously twice daily. 
She was kept on subcutaneous heparin for 6 months, and the 
signs of DVT disappeared. No recurrence of DVT was noticed 
during her follow-up over 10 years.
Discussion
IBDs are common in developed countries and are considered 
to be rare in developing countries. This is specially so for CD, 
which was described in 1932 and can affect any part of the 
gastrointestinal tract.12 It is common in developed countries, 
and the incidence is increasing worldwide. For many years, 
IBD in general and CD in particular were considered very rare 
or nonexistent in Saudi Arabia.7–9 In 1982, the first two cases 
of CD were reported from Saudi Arabia.13 Since then, several 
reports were published from Saudi Arabia but in all the num-
ber of CD patients was small. The largest series reported was 
from King Faisal Specialist Hospital and Research Center, a 
tertiary care facility.9 They reported 28 patients with CD seen 
over a period of 18 years. Subsequently, the number of cases 
reported increased. A large epidemiological study reported 
77 patients with CD seen over a period of 20 years from 
a large teaching hospital.8 This and other studies reported 
an increase in the incidence of CD in Saudi Arabia.7–9 In a 
previous study over a 20-year period, the annual incidence 
of CD increased from 0.32:100,000 in the first 10 years to 
1.66:100,000 in the subsequent 10 years.8 The reason for 
this increase is not exactly known. One factor is increased 
awareness of the disease and improved diagnostic criteria. 
To this add environmental factors and a change in dietary 
habits. Westernization of dietary habits and exposure to 
more psychological stresses may have played a role in the 
increased incidence of CD in Saudi Arabia.
The clinical manifestations of IBD are variable depend-
ing on the extent of the disease, but abdominal pain, diar-
rhea, and weight loss are the main presenting symptoms. 
One of the rare presentations of IBD that is now being 
recognized with increasing frequency and considered to be 
an extraintestinal manifestation is TE.1–3 The development 
of TE is usually associated with probable risk factors such 
as prolonged immobilization, prior surgery, and the presence 
of occult neoplasm or an already existing hypercoagulable 
disorder. IBD is now considered a risk factor for TE, but 
the reported frequency is variable.3,4 Patients with UC or 
CD have a three-fold risk of developing TE, but the actual 
incidence is not known.4 It has been reported to range from 
1% to 10% in clinical studies and from 39% to 41% in post-
mortem studies.2,5,14,15 In two large cohort studies, the overall 
incidence of TE was about 6.5% in both UC and CD.4,16 This 
is nearly six-fold higher in autopsies when compared with 
clinical studies. The reason for this higher incidence of TE 
in postmortem studies is the fact that a large number of them 
are silent and may remain so or manifest as a pulmonary 
embolism like in our patients. In one, TE was discovered 
incidentally, whereas in four it was complicated by pulmo-
nary embolism. Deep vein thrombosis and pulmonary embo-
lism are the most common types of TE seen in IBD, but there 
are reports of TE occurring in unusual sites such as cerebral, 
innominate, retinal, hepatic, and mesenteric veins as well as 
arterial TE.16,17 Our second patient had superior mesenteric 
vein thrombosis, but our third patient developed left carotid 
artery thrombosis and right popliteal deep vein thrombosis. 
The reason for this association of TE and IBD is not exactly 
known, and several factors have been incriminated. These 
include the general factors associated with increased risk for 
TE in general, such as hospitalization, immobilization, and 
recent surgery. Several other factors have also been proposed 
to explain the development of TE in IBD, including platelets 
and coagulation cascade abnormalities as well as factor V Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Leiden mutation and hyperhomocysteinemia.1–4 This was 
demonstrated in our second patient, in whom low levels of 
antithrombin III and factor V Leiden were found (Table 1). 
The extent of the disease (pancolonic   inflammation in UC 
and colonic involvement in CD) was also shown to corre-
late positively with the risk of developing TE, but it must 
be borne in mind that proctocolectomy does not protect 
from developing TE in these patients.1,17 In a review of 98 
patients with IBD and TE, it was found that UC patients 
had extensive colonic involvement and most of the patients 
with CD had colonic involvement.1 Our third patient had 
severe pancolitis. Another important correlating factor for 
the development of TE in both UC and CD is the disease 
activity, as 79% of patients with UC and 80% of patients 
with CD with an intact colon had active disease at the time 
of TE diagnosis.1
Venous TE is a serious complication of IBD that is asso-
ciated with high morbidity and mortality.1 Taking this into 
consideration, these patients must be followed up closely 
and investigated for this possibility, because in some of 
these patients TE may be silent to start with and manifest as 
pulmonary embolism, which can be fatal. They should also 
be investigated for the presence of hypercoagulable states 
including factor V Leiden mutation and hyperhomocysteine-
mia. In the presence of such conditions, lifelong anticoagu-
lation with warfarin is recommended.1,2,4,5 In the presence 
of contraindication for lifelong anticoagulation, temporary 
anticoagulation with low-molecular-weight heparin should 
be considered perioperatively, during hospitalization, and 
immobilization.
In conclusion, TE is a serious and life-threatening com-
plication of IBD. IBD is relatively rare in Saudi Arabia, but 
the incidence is increasing. This report describes six patients 
with IBD complicated by TE and pulmonary embolism. This 
complication should be borne in mind, and physicians caring 
for these patients must be aware of this, as early diagnosis is 
important in order to obviate the risks of subsequent morbid-
ity and mortality. The decision to start anticoagulant therapy 
in these patients must, however, be weighed against the 
potential risk of bleeding, and the treatment of TE in these 
patients needs to be standardized.
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